anti-CAXII monoclonal antibody

An anti-CAXII monoclonal antibody is a type of targeted biologic therapy designed to bind specifically to carbonic anhydrase XII (CAXII, also known as CA12), a membrane-associated enzyme overexpressed in various hypoxic and solid tumors, including glioblastoma, breast cancer, renal cell carcinoma, and lung cancer. CAXII plays a critical role in tumor cell survival, pH regulation, and the microenvironmental acidification that drives invasion, metastasis, and chemoresistance (often by modulating P-glycoprotein activity). Monoclonal antibodies targeting CAXII, such as the well-characterized clone 6A10 (originally developed by researchers at Helmholtz Munich) and various humanized derivatives, work by binding to the extracellular catalytic domain of the enzyme, directly inhibiting its hydration activity and disrupting intracellular/extracellular pH homeostasis. This inhibition can suppress tumor growth, reduce spheroid viability, and sensitize cancer cells to chemotherapy. Additionally, anti-CAXII antibodies are being explored as diagnostic biomarkers and as targeting moieties for radioimmunotherapy (such as the Lutetium-177-labeled Fab fragment LuCaFab/ITM-31, currently in Phase 1 clinical trials for glioblastoma).

Other names

anti-CA-XII antibodyanti-CA-XII monoclonal antibodyanti-CA12 antibodyanti-CA-12 antibodyanti-CA 12 antibodyanti-CA12 monoclonal antibodyanti-CA-12 monoclonal antibodyanti-CA 12 monoclonal antibodyanti-CAXII antibodyanti-carbonic anhydrase 12 monoclonal antibodyanti-carbonic anhydrase XII monoclonal antibody